| Headache: A striking prodromal and persistent symptom, predictive of COVID-19 clinical evolution E Caronna, A Ballvé, A Llauradó, VJ Gallardo, DM Ariton, S Lallana, ... Cephalalgia 40 (13), 1410-1421, 2020 | 221 | 2020 |
| Post-COVID-19 persistent headache: a multicentric 9-months follow-up study of 905 patients D Garcia-Azorin, A Layos-Romero, J Porta-Etessam, JA Membrilla, ... Cephalalgia 42 (8), 804-809, 2022 | 71 | 2022 |
| Headache, comorbidities and lifestyle in an adolescent population (The TEENs Study) M Torres-Ferrus, C Vila-Sala, M Quintana, S Ajanovic, VJ Gallardo, ... Cephalalgia 39 (1), 91-99, 2019 | 71 | 2019 |
| Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months E Caronna, VJ Gallardo, A Alpuente, M Torres-Ferrus, P Pozo-Rosich The journal of headache and pain 22, 1-7, 2021 | 61 | 2021 |
| The impact of anti-CGRP monoclonal antibodies in resistant migraine patients: a real-world evidence observational study M Torres-Ferrús, VJ Gallardo, A Alpuente, E Caronna, E Gine-Cipres, ... Journal of Neurology, 1-10, 2021 | 59 | 2021 |
| Salivary CGRP can monitor the different migraine phases: CGRP (in) dependent attacks A Alpuente, VJ Gallardo, L Asskour, E Caronna, M Torres-Ferrus, ... Cephalalgia 42 (3), 186-196, 2022 | 36 | 2022 |
| Influence of headache pain intensity and frequency on migraine-related disability in chronic migraine patients treated with OnabotulinumtoxinA M Torres-Ferrus, VJ Gallardo, A Alpuente, P Pozo-Rosich The journal of headache and pain 21, 1-8, 2020 | 31 | 2020 |
| Safety of anti-CGRP monoclonal antibodies in patients with migraine during the COVID-19 pandemic: Present and future implications E Caronna, VJ Gallardo, A Alpuente, M Torres-Ferrus, ... Neurologia 36 (8), 611-617, 2021 | 29 | 2021 |
| Salivary CGRP and erenumab treatment response: towards precision medicine in migraine A Alpuente, VJ Gallardo, L Asskour, E Caronna, M Torres‐Ferrus, ... Annals of Neurology 92 (5), 846-859, 2022 | 28 | 2022 |
| In search of a gold standard patient-reported outcome measure to use in the evaluation and treatment-decision making in migraine prevention. A real-world evidence study A Alpuente, VJ Gallardo, E Caronna, M Torres-Ferrus, P Pozo-Rosich The Journal of Headache and Pain 22, 1-10, 2021 | 24 | 2021 |
| Early efficacy and late gain in chronic and high‐frequency episodic migraine with onabotulinumtoxinA A Alpuente, VJ Gallardo, M Torres‐Ferrus, J Alvarez‐Sabin, ... European Journal of Neurology 26 (12), 1464-1470, 2019 | 23 | 2019 |
| Partial and nonresponders to onabotulinumtoxinA can benefit from anti‐CGRP Monoclonal antibodies preventive treatment: a real‐world evidence study A Alpuente, VJ Gallardo, E Caronna, M Torres‐Ferrús, P Pozo‐Rosich European Journal of Neurology 28 (7), 2378-2382, 2021 | 21 | 2021 |
| The relationship of headache as a symptom to COVID‐19 survival: A systematic review and meta‐analysis of survival of 43,169 inpatients with COVID‐19 VJ Gallardo, RE Shapiro, E Caronna, P Pozo‐Rosich Headache: The Journal of Head and Face Pain 62 (8), 1019-1028, 2022 | 17 | 2022 |
| Short and mid‐term predictors of response to onabotulinumtoxina: Real‐life experience observational study A Alpuente, VJ Gallardo, M Torres‐Ferrús, J Álvarez‐Sabin, ... Headache: The Journal of Head and Face Pain 60 (4), 677-685, 2020 | 16 | 2020 |
| Cluster Headache Genomewide Association Study and Meta‐Analysis Identifies Eight Loci and Implicates Smoking as Causal Risk Factor BS Winsvold, AVE Harder, C Ran, MA Chalmer, MC Dalmasso, ... Annals of Neurology 94 (4), 713-726, 2023 | 14 | 2023 |
| OnabotulinumtoxinA: an effective tool in the therapeutic arsenal for chronic migraine with medication overuse E Caronna, VJ Gallardo, N Hernández-Beltrán, M Torres-Ferrus, ... Frontiers in neurology 9, 808, 2018 | 14 | 2018 |
| Cortical metabolic and structural differences in patients with chronic migraine. An exploratory 18FDG-PET and MRI study M Torres-Ferrus, D Pareto, VJ Gallardo, G Cuberas-Borrós, A Alpuente, ... The Journal of Headache and Pain 22, 1-11, 2021 | 13 | 2021 |
| The impact of headache disorders on COVID-19 survival: a world population-based analysis RE Shapiro, VJ Gallardo, E Caronna, P Pozo-Rosich medRxiv, 2021.03. 10.21253280, 2021 | 11 | 2021 |
| Patterns of response to anti‐calcitonin gene‐related peptide monoclonal antibodies during first 6 months of treatment in resistant migraine patients: Impact on outcome M Torres‐Ferrus, VJ Gallardo, A Alpuente, E Caronna, E Giné‐Ciprés, ... European Journal of Neurology 30 (7), 1937-1944, 2023 | 7 | 2023 |
| The impact of epigenetic mechanisms in migraine: Current knowledge and future directions VJ Gallardo, M Vila-Pueyo, P Pozo-Rosich Cephalalgia 43 (2), 03331024221145916, 2023 | 7 | 2023 |
